Trials / Unknown
UnknownNCT01548274
Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Aichi Gakuin University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effects of Sarpogrelate in endothelial progenitor cells of patients with atherosclerosis.
Detailed description
Endothelial progenitor cells play an important role in vasculogenesis and vascular repair. Sarpogrelate, a inhibitor of HT2A, is used an an anti-platelet drug, however, a direct effect in vascular cells is supposed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sarpogrelate | Sarpogrelate 300mg/day |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2012-03-08
- Last updated
- 2012-03-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01548274. Inclusion in this directory is not an endorsement.